- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38 result(s) found for: Interleukin 13.
Displaying page 1 of 2.
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2012-005713-39 | Sponsor Protocol Number: 42970 | Start Date*: 2014-09-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Ongoing) ES (Prematurely Ended) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003751-42 | Sponsor Protocol Number: ICH-013-UroNEOadI | Start Date*: 2022-01-25 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms. | |||||||||||||
Medical condition: Patients with primary treatment-naïve vesical neoplasms. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003858-33 | Sponsor Protocol Number: AM0010-301 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi... | |||||||||||||
Medical condition: Advanced Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000649-77 | Sponsor Protocol Number: C0743T26 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Centocor BV | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003050-23 | Sponsor Protocol Number: VTX002-201 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Oppilan Pharma Ltd., wholy owned subsidiary of Ventyx Biosciences Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcer... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) PL (Ongoing) HU (Ongoing) LT (Ongoing) IT (Ongoing) BG (Ongoing) SK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001656-41 | Sponsor Protocol Number: TCeD21 | Start Date*: 2022-12-07 |
Sponsor Name:Topas Therapeutics GmbH | ||
Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno... | ||
Medical condition: Coeliac disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Ongoing) FI (Ongoing) DE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002031-29 | Sponsor Protocol Number: R7257-RAA-1947 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ... | |||||||||||||
Medical condition: SEVERE APLASTIC ANEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021018-49 | Sponsor Protocol Number: FOILED | Start Date*: 2012-05-25 | ||||||||||||||||
Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
Full Title: Fish OIL optimal dosE Determination Study | ||||||||||||||||||
Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015936-14 | Sponsor Protocol Number: CH14.181021 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:University Children´s Hospital Tübingen, | |||||||||||||
Full Title: PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA | |||||||||||||
Medical condition: Pediatric patients with relapsed neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001152-29 | Sponsor Protocol Number: 201956 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study | |||||||||||||
Medical condition: Subjects with severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) CZ (Completed) EE (Completed) SK (Completed) GR (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020798-17 | Sponsor Protocol Number: HGS1012-C1103 | Start Date*: 2011-07-01 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | |||||||||||||
Full Title: A Randomized, Multi-Center, Blinded, Placebo-Controlled Study of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First-Line Therapy in Subj... | |||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018585-23 | Sponsor Protocol Number: A4061051 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC) | |||||||||||||
Medical condition: metastatic renal cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003303-14 | Sponsor Protocol Number: DETACT | Start Date*: 2023-02-16 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT) | ||
Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001540-56 | Sponsor Protocol Number: 208657 | Start Date*: 2019-08-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Ongoing) ES (Ongoing) NL (Ongoing) DK (Ongoing) BE (Ongoing) DE (Ongoing) SE (Ongoing) IE (Ongoing) IT (Ongoing) GR (Ongoing) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005441-32 | Sponsor Protocol Number: DIAGNODE-B | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:Linköping University | |||||||||||||
Full Title: DIAGNODE-B, A Phase I/II Open Label Pilot Study to evaluate the safety and feasibility of an additional intralymphatic booster administration of GAD-alum (Diamyd®) in individuals with Type 1 diabetes | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.